Abstract

Background Recent studies have shown that the expression level of triosephosphate isomerase 1 (TPI1) may be associated with the occurrence and metastasis of tumors, but the expression level of TPI1 and its effect on lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC) are not yet clear. Methods We comprehensively explored and validated the TPI1 expression in lung adenocarcinoma and lung squamous cell carcinoma in public datasets. The associations of TPI1 expression with clinicopathological characteristics and prognosis were also studied in both histological types. Moreover, we analyzed the potential relations of TPI1 with immunomodulators and immune cell infiltrations in the tumor microenvironment based on previous literatures and bioinformatic tools. Results We found that TPI1 was significantly overexpressed in LUAD and LUSC. Significant associations of TPI1 expression were observed regarding age, gender, and pathological stages in LUAD. However, similar trend was only found with respect to age in LUSC. The high expression of TPI1 was significantly associated with worse survival in LUAD, but not in LUSC. Furthermore, we explored the potential distribution and changes of TPI1 expression in tumor microenvironment. Pathway enrichment analyses were performed to identify possible roles of TPI1 in both lung cancers. Conclusions TPI1 was overexpressed in both LUAD and LUSC. Increased TPI1 expression was correlated with poor prognosis in LUAD and changed immune cell infiltrating in various degrees in both histological types. Our study provides insights in understanding the potential roles of TPI1 in tumor progression and immune microenvironment.

Highlights

  • Lung cancer is one of the most commonly diagnosed cancers, with over 1,700,000 new cases every year [1, 2]

  • Our study provides insights in understanding the potential roles of triosephosphate isomerase 1 (TPI1) in tumor progression and immune microenvironment, which lay the foundation for future clinical research

  • We studied the potential associations of TPI1 expression with immunomodulators and chemokines in The Cancer Genome Atlas (TCGA) lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) cohorts

Read more

Summary

Introduction

Lung cancer is one of the most commonly diagnosed cancers, with over 1,700,000 new cases every year [1, 2]. The expression changes and underlying roles of TPI1 in LUAD and LUSC remain unknown. Recent studies have shown that the expression level of triosephosphate isomerase 1 (TPI1) may be associated with the occurrence and metastasis of tumors, but the expression level of TPI1 and its effect on lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC) are not yet clear. We analyzed the potential relations of TPI1 with immunomodulators and immune cell infiltrations in the tumor microenvironment based on previous literatures and bioinformatic tools. The high expression of TPI1 was significantly associated with worse survival in LUAD, but not in LUSC. Increased TPI1 expression was correlated with poor prognosis in LUAD and changed immune cell infiltrating in various degrees in both histological types. Our study provides insights in understanding the potential roles of TPI1 in tumor progression and immune microenvironment

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.